TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.

doi:10.1038/s41416-026-03548-1

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.

British journal of cancer - 1 Oct 2026

Su Xiaohe, Jin Kaifeng, Zeng Han, Liu Zhaopei, Zhang Lingkai, Ding Yawei, Sun Jiaxing, Wu Yuzhen, Liu Hailong, Chang Yuan, Xu Le, Zhang Weijuan, Wang Zewei, Zhu Yu, Xu Jiejie

Abstract excerpt

BACKGROUND: Emerging evidence has underscored non-cell-autonomous roles of mutant p53 in reshaping the composition and functional state of tumour immune microenvironment (TIME). However, the impact of p53 status on the clinical relevance and functional differentiation of CD8+ T cells remains poorly understood in urothelial carcinoma (UC). METHODS: Our study included 297 UC patients from two in-house cohorts and...

Read the complete abstract on PubMed

Topics

Humans
T-Cell Exhaustion
CD8-Positive T-Lymphocytes
Tumor Suppressor Protein p53
Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Female

Tumor Microenvironment

Prognosis

Drug Resistance, Neoplasm

Male

Urinary Bladder Neoplasms

Carcinoma, Transitional Cell

Middle Aged

Hepatitis A Virus Cellular Receptor 2

Aged

Lymphocytes, Tumor-Infiltrating

Source

Open in PubMed Open full text

Identifiers

PMID: 42436321
DOI: 10.1038/s41416-026-03548-1
PMCID: PMC13578338

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma.PMID 42436321Read ↗

Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma.Semantic proximity Read ↗

A TP53-Associated Immune Prognostic Signature for the Prediction of Overall Survival and Therapeutic Responses in Muscle-Invasive Bladder Cancer.Semantic proximity Read ↗

Alterations in TP53 Are a Potential Biomarker of Bladder Cancer Patients Who Benefit From Immune Checkpoint Inhibition.Semantic proximity Read ↗

TP53 mutations in urothelial carcinoma: not all one and the same†.Semantic proximity Read ↗

Master regulator: p53’s pivotal role in steering NK-cell tumor patrolSemantic proximity Read ↗

The impact of p53 mutation on tumor immune evasion: mechanistic insights and clinical implications.Semantic proximity Read ↗

SnapShot: TP53 status and macrophages infiltration in TCGA-analyzed tumors.Semantic proximity Read ↗

TP53 gain-of-function mutation modulates the immunosuppressive microenvironment in non-HPV-associated oral squamous cell carcinoma.Semantic proximity Read ↗

Oncogenic PIK3CA mutation enhances tumor immunogenicity through the IRF1-NLRC5-MHC-I axis in urothelial carcinoma.Semantic proximity Read ↗

Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancerSemantic proximity Read ↗

T Cell-to-Stroma Enrichment (TSE) score: a gene expression metric that predicts response to immune checkpoint inhibitors in patients with urothelial cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.